Retatrutide is an investigational peptide that activates three hormone receptors: GLP-1, GIP and glucagon. This combination targets pathways involved in appetite, glucose regulation and energy metabolism. Human clinical trials have reported substantial weight loss and improvements in blood-glucose control, although the contribution of each receptor to these outcomes remains under investigation. Retatrutide remains unapproved, and its safety and efficacy continue to be evaluated in clinical trials.
Retatrutide is an investigational peptide that activates three hormone receptors: GLP-1, GIP and glucagon. This combination targets pathways involved in appetite, glucose regulation and energy metabolism. Human clinical trials have reported substantial weight loss and improvements in blood-glucose control, although the contribution of each receptor to these outcomes remains under investigation. Retatrutide remains unapproved, and its safety and efficacy continue to be evaluated in clinical trials.
Image 1 of 2
Image 2 of 2
